Skip to main content

Acute Myeloid Leukemia: Decision-Making Steps in Treatment

Module #2 in the series, AML Strategies: Decision-Making at Each Point in Care

This is part 2 of a 3-module series. To access the other modules, click here.

Click Here to Participate 

1.0 CE Credit Available Until: October 31, 2022
Format: Interactive recorded webinar


Target Audience

The target audience includes hematology/oncology nurses, physician assistants, nurse practitioners, transplant clinicians, and other members of the multidisciplinary cancer care team who are involved in the diagnosis and management of patients with AML. 



This educational activity will provide members of the multidisciplinary cancer care team with the latest information to improve their knowledge and confidence in the diagnosis and treatment of AML through interactive online activities. Topics in this module include choosing the appropriate tests to diagnose AML, identifying therapeutic options for management based on the results of diagnostic tests, monitoring patients for adverse events, and how to develop an individualized treatment plan.

Learning Objectives:

Upon completion of the activity, participants should be able to do the following:

  • Choose appropriate tests to diagnose AML
  • Review therapeutic options for management of AML
  • Establish an appropriate sequence of therapies
  • Monitor patients for adverse events associated with treatment and manage them accordingly

Steering Committee/Faculty:

Jessica Altman, MD (Faculty Advisor and Chair)
Professor of Medicine
Hematology Oncology Division
Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL

Tara L Lin, MD
Director, Acute Leukemia Program
Professor of Internal Medicine
Division of Hematologic Malignancies & Cellular Therapeutics
University of Kansas Cancer Center
Kansas City, KS 

Angela O Hatcher, PA-C, MPH 
Physician Assistant, Hematology/Leukemia
Winship Cancer Institute of Emory University
Atlanta, GA

Continuing Education

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Nurse Practitioners


This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.75 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 21105210. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Physician Assistants


This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 9/30/2021 to 9/29/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-203223

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

ILNA Categories and Points: Care Continuum 1| Coordination of Care 1| Symptom Management 1| Treatment 1| Total Maximum = 1 ILNA Points  

Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum amount of points that can be claimed in each subject area.  The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Provider statement
This activity is provided by The Leukemia & Lymphoma Society and produced in collaboration with The France Foundation, the American Society of Hematology, and the American Society for Clinical Pathology.



This activity is supported by educational grants from Astellas and Bristol Myers Squibb.


Click Here to Participate 

Participants gain access to the webinar via the registration button above.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at

< Back to Continuing Education